TAIPEI, Taiwan, Nov. 15, 2022 /PRNewswire/ — QPS, a global contract research organization, recently opened a second preclinical research facility in Taipei, Taiwan. The 2,793-square-foot facility will facilitate an expansion of research into additional toxicology studies and a newly launched capacity in pharmacology studies.
The new facility will be operational in December 2022 and will give QPS significant additional flexibility in study scheduling and additional space to grow the existing toxicology business and build out the new pharmacology unit.
Designed to ensure the utmost care is taken with all toxicology and pharmacology studies, this new research facility features well-equipped, fully accredited animal centers and a state-of-the-art pharmacology unit. Initially, the center will focus on augmenting current multispecies capabilities in wound healing models, with pharmacology services in irritable bowel disease (IBD), non-alcoholic steatohepatitis (NASH), and atopic dermatitis. The team will be ready to conduct these studies on a variety of species in early 2023.
“Preclinical research in multiple species is a crucial step in the drug development process. Assessing toxicology and safety at these early stages of the research process helps ensure that new drugs are safe enough to allow them to progress.” clinical research trials conducted first in humans (FIH),” said Dr. Chen, Deputy General Manager and Director of the Center for Toxicology and Preclinical Sciences (CTPS) at QPS Taiwan.
QPS has hired Dr. Mei-Ling Hou, PhD to lead the new pharmacology department. Hou joins QPS from the Department of Pharmacology and Toxicology at the Institute for Drug Evaluation Platform, Development Center for Biotechnology (DCB). Dr. Hou’s experience will strongly drive the growth and development of this new pharmacology service.
This new center of excellence, which aligns with the biotech and pharmaceutical industry from pre-clinical to clinical studies, will ensure that QPS has the skills, capabilities and space to fully implement global projects related to pharmaceutical and biotech pharmacology and toxicology.
ABOUT QPS HOLDINGS, LLC
QPS is a GLP and GCP compliant contract research organization (CRO) providing the highest degree of discovery, preclinical and clinical drug development services. Since 1995, it has grown from a small bioanalysis shop to a full-service CRO with more than 1,200 employees in the United States, Europe, and Asia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in neuropharmacology, DMPK, toxicology, bioanalysis, translational medicine, and clinical development. Through continuous enhancements in capabilities and resources, QPS remains steadfast in its commitment to providing superior quality, qualified performance and reliable service to its valued customers. For more information, visit www.qps.com or email info@qps.com.
Contact: Gabrielle Pastore, QPSTel: 302-635-4290E-mail: gabrielle.pastore@qps.com
Photo – link
View original content: enlace
